Prevention of hepatitis B virus reactivation in immunosuppressive therapy or chemotherapy
Authors:
- 1 October 2011
- journal article
- review article
- Published by Springer Nature in Clinical and Experimental Nephrology
- Vol. 15 (5) , 634-640
Abstract
In recent years, hepatitis B virus (HBV) has been found to reproliferate either during or following immunosuppressive therapy or chemotherapy, with hepatitis caused by HBV reactivation now considered a serious issue. HBV reactivation is categorized into occurrence in HBsAg- and anti-HBe-positive asymptomatic carriers, and in HBsAg-negative, anti-HBc low-titer-positive, and/or anti-HBs-positive resolved HBV infection cases. Despite the fact that “clinical cure” is claimed for such resolved HBV cases, low levels of ongoing HBV production are now recognized as being sustained within the liver or in peripheral blood mononuclear cells, with the infection thus now considered to be virologically persistent. The risk of HBV reactivation rises as the level of immunosuppression intensifies, but in recent years HBV reactivation risk has been clearly shown to increase in cases of rituximab plus steroid-containing regimen for treatment of malignant lymphoma. In particular, the incidence of fulminant hepatitis caused by HBV reactivation in cases with resolved HBV infection is reported to be higher than that brought about by acute hepatitis B. Therefore, for all cases in which immunosuppressive therapy or chemotherapy treatment regimens are used, screening for HBV infection and appropriate management in accordance with the status of HBV-related markers are crucial, aimed at preventing occurrence of HBV reactivation. The foundation of the aforementioned management, regardless of HBsAg status, is administration of nucleoside analogues, with their powerful anti-viral properties, when HBV DNA levels reach detectable levels.Keywords
This publication has 61 references indexed in Scilit:
- Reactivation of hepatitis B virus following rituximab-plus-steroid combination chemotherapyJournal of Gastroenterology, 2010
- Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-naïve patients is rare through 5 years of therapy #Hepatology, 2009
- Hepatitis B Virus Reactivation in Lymphoma Patients With Prior Resolved Hepatitis B Undergoing Anticancer Therapy With or Without RituximabJournal of Clinical Oncology, 2009
- Rituximab for refractory focal segmental glomerulosclerosisPediatric Nephrology, 2007
- Rituximab therapy for steroid-dependent minimal change nephrotic syndromePediatric Nephrology, 2006
- Chronic hepatitis B reactivation following infliximab therapy in Crohn’s disease patients: need for primary prophylaxisGut, 2004
- Hepatitis B virus reactivation with clinical flare in allogeneic stem cell transplants with chronic graft-versus-host diseaseBone Marrow Transplantation, 2002
- Glucocorticoids in T Cell Development and FunctionAnnual Review of Immunology, 2000
- Growth Inhibition of CD20‐positive B Lymphoma Cell Lines by IDEC‐C2B8 Anti‐CD20 Monoclonal AntibodyJapanese Journal of Cancer Research, 1998
- Short-term prednisolone for inducing seroconversion from hepatitis B e antigen to antibody along with clinical improvement in patients with chronic active hapatitis type B.Japanese Journal of Medicine, 1987